Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Zymeworks Inc. - Common Stock (NQ:ZYME)

12.29 +0.47 (+3.98%)
Streaming Delayed Price Updated: 12:32 PM EDT, May 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Zymeworks Inc. - Common Stock

< Previous 1 2 Next >
Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference
From Zymeworks Inc.
Via GlobeNewswire
What Analysts Are Saying About Zymeworks Stock
Via Benzinga
Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks to Report Third Quarter 2024 Financial Results and Host Conference Call on October 31, 2024
From Zymeworks Inc.
Via GlobeNewswire
Navigating 6 Analyst Ratings For Zymeworks
Via Benzinga
Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference
Presentations to highlight progress in development of IND candidates ZW220 and ZW251 based on Zymeworks’ proprietary antibody-drug conjugate development platforms 
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Reports Inducement Grant Under Nasdaq Stock Market Rule 5635(c)
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Announces Share Repurchase Program of up to $60 Million of its Common Stock
Zymeworks intends to commence the Share Repurchase Program with $30.0 million in initial repurchases anticipated to begin promptly and continue during the second half of 2024 
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Provides Corporate Update and Reports Second Quarter 2024 Financial Results
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Appoints Leone Patterson as Chief Business and Financial Officer
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW191, a Novel Folate Receptor-⍺ Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks To Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers
From Zymeworks Inc.
Via GlobeNewswire
Week In Review: Osaka Enters $445 Million Deal For Two Hearing Loss Candidates From France's Cilcare
Shionogi, an Osaka innovative pharma, has signed an option agreement with Cilcare of France to in-license two drug candidates aimed at hearing loss in a deal worth up to $445 million. Meanwhile, XtalPi... 
Via Talk Markets
Zymeworks Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer
From Zymeworks Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.